Oltipraz is primarily used in research settings to study its potential chemopreventive properties. It has been investigated for its ability to protect against carcinogenesis, particularly in liver and colon cancers, by modulating detoxification enzymes and enhancing the body's defense mechanisms against toxic substances. Additionally, it has been explored for its anti-schistosomal properties, showing effectiveness in treating schistosomiasis, a parasitic disease caused by Schistosoma species. Its role in reducing oxidative stress and inflammation has also been a focus in various preclinical studies.